Methods for assessing and treating leukemia

• US 20070048782A1
• Filed: 10/30/2006
• Published: 03/01/2007
• Est. Priority Date: 10/30/2001
• Status: Abandoned Application

• Current Assignee: Veridex LLC (Johnson & Johnson)
• Original Assignee: Veridex LLC (Johnson & Johnson)
• Inventors: Raponi, Mitch
• Application Number:
  US11/589,660
• Publication Number:
  US 20070048782A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

Methods for treating leukemia patients include analyzing gene expression profiles of a patient to determine whether the patient is likely to respond to treatment with farnesyl transferase inhibitor (FTI) and, optionally, other therapeutics. The methods are also useful for monitoring patient therapy and for selecting a course of therapy. Genes modulated in response to FTI treatment are provided and are used in formulating the profiles.

Claims

1. A method of determining whether a patient with acute myelogenous leukemia will respond to treatment with an FTI by (a) analyzing a diseased cell from a bone marrow sample from the patient for a detectable difference in the amount of expression of a gene comprising Seq. ID. No. 846 (343105F7) following treatment with an FTI relative to an untreated diseased cell;

(b) comparing the detectable difference from step (a) to those obtained from responder and non-responder patients; and

(c) correlating the patient expression patter with that of a responder or non-responder to said FTI.

2. The method of claim 1 wherein the diseased cells are hematopoietic blast cells.

3. The method of claim 1 wherein the analysis step (a) is carried out using a nucleic acid array.

4. The method of claim 3 wherein the detectable difference is at least 1.5 fold compared to the expression of said genes in said non-responder.

5. The method of claim 3 wherein the detectable difference is at least 1.7 fold compared to the expression of said genes in said non-responder.

6. The method of claim 3 wherein the detectable difference is at least 2 fold compared to the expression of said genes in said non-responder.

7. The method of claim 1 wherein the FTI is selected from the group consisting of 7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1H-imidazol-1-ylmeth-yl]-2,3-dihydro-1H,5H-benzo[ij]quinolizin-5-one, 7-(3- chlorophenyl)-9-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quin-oline-4-one, 8-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-6-(3-chlorophen yl)-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one, 8-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-6-(3-chlorophe-nyl)-2,3-dihydro-1H,5H-benzo[ij]quinolizin-5-one, and (B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlor-ophenyl)-1-methyl-2(1H)-quinolinone).

8. The method of claim 7 wherein the FTI is (B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinoli-none).

9. A method of monitoring treatment response in a patient with acute myelogenous leukemia will respond to treatment with an FTI by (a) analyzing a diseased cell from a sample from the patient for a detectable difference in the amount of expression of a gene comprising Seq. ID. No. 846 (343105F7) at various periods throughout the course of treatment with said FTI;

(b) comparing the expression pattern of step (a) to those obtained from responder and non-responder patients; and

(c) correlating the patient expression patter with that of a responder or non-responder to said FTI to determine whether to adjust the treatment of the patient.

10. The method of claim 9 wherein the diseased cells are hematopoietic blast cells.

11. The method of claim 9 wherein the analysis step (a) is carried out using a nucleic acid array.

12. The method of claim 9 wherein the detectable difference is at least 1.5 fold compared to the expression of said genes in said non-responder.

13. The method of claim 9 wherein the detectable difference is at least 1.7 fold compared to the expression of said genes in said non-responder.

14. The method of claim 9 wherein the detectable difference is at least 2 fold compared to the expression of said genes in said non-responder.

15. The method of claim 9 wherein the FTI is selected from the group consisting of 7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1H-imidazol-1-ylmeth-yl]-2,3-dihydro-1H,5H-benzo[ij]quinolizin-5-one, 7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quin-oline-4-one, 8-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-6-(3-chlorophen yl)-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one, 8-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-6-(3-chlorophe-nyl)-2,3-dihydro-1H,5H-benzo[ij]quinolizin-5-one, and (B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlor-ophenyl)-1-methyl-2(1H)-quinolinone).

16. The method of claim 15 wherein the FTI is (B)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinoli-none).